Rethinking Obesity: Landmark Study Maps Clinical Obesity Across the Human Lifespan

Obesity has long been measured by a single number: body mass index. But a sweeping new analysis of nearly 800,000 people across seven high-income countries suggests that this familiar metric tells only part of the story, and that the gap between what a scale reveals and what is actually happening inside the body shifts dramatically as we age. The study, published in EClinicalMedicine, applied the new Lancet Commission definition of clinical obesity to data spanning early childhood to old age, and its findings could reshape how doctors, researchers, and policymakers think about who truly needs treatment.

The Lancet Diabetes and Endocrinology Commission, in its 2025 report, proposed a fundamental reframing of obesity. Rather than treating a high BMI as a diagnosis in itself, the Commission distinguished between clinical obesity, in which excess body fat is accompanied by measurable organ dysfunction or limitations in daily activities, and preclinical obesity, in which excess fat has not yet caused observable harm. The distinction matters because BMI is an imperfect proxy: it overestimates adiposity in muscular individuals and underestimates it in people with central fat accumulation but normal weight. By requiring evidence of organ dysfunction, the new framework aims to identify people whose excess fat is actively damaging their health.

Applying this framework at population scale required an unprecedented collaborative effort. No single cohort had collected all the anthropometric measures, body composition data, and clinical and laboratory markers the Commission’s criteria demand. So the research consortium, known as ECOS, integrated cross-sectional data from 11 population-based cohorts in Australia, Canada, Estonia, Finland, the Netherlands, the United Kingdom, and the United States, covering 44 assessment waves collected between 1996 and 2023. In total, 786,557 participants aged four and above were classified, making this the largest clinical obesity prevalence study conducted to date.

The results reveal a striking age-dependent divergence between BMI-defined and clinical obesity. In early childhood, clinical obesity affected just 3.7 percent of children aged four to five, well below the 8.8 percent prevalence of BMI-defined obesity in the same group. Throughout childhood, adolescence, and early and mid-adulthood, BMI-defined obesity consistently overestimated the burden of clinically significant disease. At ages 35 to 44, for example, 26.3 percent of participants met BMI criteria for obesity, but only 15.1 percent met the Commission’s criteria for clinical obesity. Then the pattern inverts: from age 55 onward, clinical obesity becomes more common than BMI-defined obesity, climbing to 52.0 percent among adults aged 65 to 74.

The organ dysfunction criteria driving these classifications varied systematically with age. Among children with clinical obesity, elevated systolic blood pressure was overwhelmingly the most common finding, present in 87.3 percent of affected four- to nine-year-olds. Renal dysfunction, detected through microalbuminuria, was also most prevalent in childhood, affecting 44.2 percent of young children with clinical obesity. In early and mid-adulthood, liver dysfunction took center stage, with elevated alanine aminotransferase found in 56.3 percent of affected adults aged 20 to 34 and elevated gamma-glutamyl transferase in 48.8 percent of those aged 35 to 54. In later life, musculoskeletal dysfunction dominated, affecting 55.1 percent of people aged 75 and older with clinical obesity.

Sex emerged as a powerful modifier of these patterns. From adolescence through mid-adulthood, males carried a higher prevalence of clinical obesity than females; at ages 35 to 44, 18.6 percent of men versus 13.9 percent of women met the criteria. But from age 55 onward the relationship reversed, with women showing markedly higher prevalence. At ages 65 to 74, 57.1 percent of women had clinical obesity compared with 44.1 percent of men, and female prevalence peaked at 58.5 percent at ages 75 to 84. Preclinical obesity followed a different trajectory: in women it rose through early adulthood, peaked in the mid-thirties to mid-forties, and then declined, whereas in men it remained relatively constant across the life course. The authors suggest these divergences may partly reflect survival bias and differences in how excess adiposity manifests between the sexes, though the underlying biology remains to be fully explored.

Socioeconomic position, measured through education level, showed a more modest influence. Across all age groups, clinical obesity prevalence was slightly lower among people with high education compared with those in the middle and low education categories; at ages 65 to 74, prevalence was 46.8 percent in the high education group versus 53.9 and 55.0 percent in the middle and low groups respectively. The age-dependent patterns of both clinical and preclinical obesity were broadly similar across all three education strata, suggesting that while education shapes obesity risk, the relationship between excess fat and organ dysfunction follows a comparable life course architecture regardless of socioeconomic background.

The study also exposed how sensitive prevalence estimates are to the specific measures chosen to define excess adiposity. In a subgroup of cohorts with complete anthropometric and body composition data, waist-to-height ratio was met by virtually all participants classified with clinical or preclinical obesity, between 95.4 and 100 percent depending on the cohort, while body fat percentage was the least commonly satisfied criterion, met by as few as 9.6 percent of UK Biobank participants with clinical obesity. When excess adiposity was defined by any two anthropometric criteria, clinical obesity prevalence in adults ranged from 5.2 percent at ages 20 to 24 to 51.2 percent at ages 65 to 74, substantially higher than estimates based on BMI plus one anthropometric measure or body fat percentage alone. These differences carry real consequences for diagnosis, risk prediction, and treatment eligibility.

The authors are candid about the limitations inherent in retrofitting a new diagnostic framework onto data collected before it existed. No cohort captured all 13 diagnostic domains specified by the Commission, meaning clinical obesity prevalence was likely underestimated in some groups. Data on central nervous system, respiratory, lymphatic, and reproductive criteria were sparse or absent, and the researchers could not always verify that observed organ dysfunction was genuinely attributable to excess adiposity rather than to other common conditions of later life. Laboratory thresholds varied across jurisdictions, and the treatment of medicated conditions, such as hypertension controlled by antihypertensive drugs, required pragmatic decisions that the Commission’s guidelines do not address. The cohorts were also predominantly from high-income, majority-White populations, limiting generalizability to more diverse settings where the burden of obesity is growing fastest.

Despite these caveats, the consistency of the life course pattern across cohorts from different countries, recruitment epochs, and measurement protocols lends weight to the central conclusion: clinical obesity is rarer than BMI-defined obesity in childhood and early adulthood, but substantially more common in later life. The findings underscore an urgent need for prospective longitudinal studies with standardized collection of all diagnostic criteria, which would allow researchers to track how individuals transition from preclinical to clinical obesity and to determine whether early identification and intervention in childhood, a critical window for prevention, can alter that trajectory. For now, the study provides the most comprehensive picture yet of what the new definition of obesity means for real populations, and it suggests that the number on the scale, and even the ratio of weight to height, may be far less informative than the quiet damage that excess fat does to organs over decades of exposure.

Subject of Research: Life course prevalence of clinical and preclinical obesity using the Lancet Commission diagnostic criteria

Article Title: The lancet commission definition of clinical obesity: a multi-cohort cross-sectional analysis from early childhood to older age in seven high-income countries

Article References: Longmore, D. K., MacKechnie, G. P., Huntington, P. A., Chen, Z. H., de Groot, J., Mikkonen, S., Mykkänen, J., Pätsi, S., Puusepp, T., Fischer, K., Jaddoe, V., Kerr, J. A., Lakka, T. A., Lehtimäki, T., Miliku, K., Nedelec, R., Ponsonby, A.-L., Sebert, S., Vuillermin, P., … Viikari, J. (2026). The lancet commission definition of clinical obesity: a multi-cohort cross-sectional analysis from early childhood to older age in seven high-income countries. eClinicalMedicine, Article 104231. https://doi.org/10.1016/j.eclinm.2026.104231

Image Credits: AI Generated

DOI: 10.1016/j.eclinm.2026.104231

Keywords: clinical obesity, preclinical obesity, Lancet Commission, body mass index, organ dysfunction, life course epidemiology, adiposity, pediatric obesity, cohort study, prevalence, metabolic health, public health